Shares of Novo Nordisk and Eli Lilly declined significantly following the announcement by telehealth company Hims & Hers of a new, lower-cost copy of the Wegovy weight-loss drug. Novo's stock dropped as much as 9%, and Eli Lilly's fell 4% in premarket trading, reflecting investor concern over increased competition and pricing pressure. Meanwhile, Hims & Hers stock surged 15%, indicating strong market interest in their $49 Wegovy alternative, which is priced substantially lower than the $149 charged by Novo Nordisk for their branded pill. This development signals a potential shift in the weight-loss medication market, with affordability becoming a critical factor.